No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 27 of the 40 quarters in the window, leaving 13 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 11.7x · 10Y median 15.1x · 4th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:01:05.465Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Axsome Therapeutics, Inc. (AXSM) stock was $177.08 as of Oct 5, 2026, 4:00 PM EDT, down 1.21% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +46.9% · 3-year avg +38.0%/yr · 5-year avg +41.4%/yr
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States.
Biotechnology · New York City, NY
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 2, 2026
27 days away
EPS Estimate
-0.51
Revenue Est.
$257.35M
Last Quarter Results
EPS
$-0.99
vs Estimate
$-0.78
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1AXSM | $9.11B | $177.08 | -1.21% | +46.93% | +41.40% | +35.76% | N/A |
| 2BRKRP | $9.35B | $466.08 | +0.06% | +62.86% | N/A | N/A | vs AXSM |
| 3PODD | $9.39B | $135.62 | +2.98% | -55.95% | -13.93% | +13.11% | vs AXSM |
| 4ARWR | $8.78B | $62.35 | -2.87% | +72.17% | +0.75% | +23.56% | vs AXSM |
| 5HSIC | $9.60B | $84.23 | -0.77% | +25.52% | +1.39% | +2.90% | vs AXSM |
| 6CAI | $8.59B | $30.39 | +7.39% | -4.35% | N/A | N/A | vs AXSM |
forward FY estimate
N/A
$216.35M
vs Estimate
$221.11M
Consensus Rating
Based on 22 analysts
Average Price Target
$284.63
+60.7% upside
Low
$246.00
Current
$177.08
High
$380.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.86 | $-0.51 | $-0.12 | 10 |
| Quarter ending Dec 2026 | $-0.27 | $0.05 | $0.64 | 9 |
| Quarter ending Mar 2027 | $0.03 | $0.05 | $0.05 | 6 |
| Quarter ending Jun 2027 | $0.44 | $0.59 | $0.68 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.79 | $-2.70 | $-1.71 | 15 |
| FY 2027 | $-4.05 | $4.51 | $9.55 | 14 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $231.60M | $257.35M | $268.20M | 13 |
| Quarter ending Dec 2026 | $241.49M | $297.16M | $321.85M | 13 |
| Quarter ending Mar 2027 | $239.96M | $297.59M | $330.93M | 6 |
| Quarter ending Jun 2027 | $280.73M | $348.15M | $387.15M | 6 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $882.23M | $962.32M | $995.30M | 16 |
| FY 2027 | $1.18B | $1.54B | $1.78B | 16 |
